The National Institutes of Health’s Blueprint Neurotherapeutics Network (BPN) is offering a grant for neuroscience investigators to advance small molecule drug discovery projects into clinical development. Funding supports activities in participants’ laboratories and collaboration with NIH-funded experts in medicinal chemistry, toxicology, clinical testing, and more. Projects can join at the Discovery stage for optimizing hit compounds or at the Development stage for advancing candidates through clinical testing. Successful projects may progress from Discovery to Development stages and participants retain intellectual property rights to developed drug candidates. Closing date for applications is March 9, 2017.
Opportunity ID: 260046
General Information
| Document Type:: | Grants Notice |
| Funding Opportunity Number:: | PAR-14-292 |
| Funding Opportunity Title:: | Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44) |
| Opportunity Category:: | Discretionary |
| Opportunity Category Explanation:: | |
| Funding Instrument Type:: | |
| Category of Funding Activity:: | Education |
| Category Explanation:: | |
| Expected Number of Awards:: | |
| Assistance Listings Number(s):: | 93.121 — Oral Diseases and Disorders Research |
| Cost Sharing or Matching Requirement:: | No |
| Version:: | Synopsis 2 |
| Posted Date:: | Jul 22, 2014 |
| Last Updated Date:: | Mar 09, 2017 |
| Original Closing Date for Applications:: | May 07, 2017 |
| Current Closing Date for Applications:: | Mar 09, 2017 |
| Archive Date:: | Apr 08, 2017 |
| Estimated Total Program Funding:: | |
| Award Ceiling:: | $ |
| Award Floor:: | $ |
Eligibility
| Eligible Applicants:: | Small businesses |
| Additional Information on Eligibility:: | Other Eligible Applicants include the following:Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. A small business concern is one that, at the time of award of Phase I and Phase II, meets all of the following criteria:1. Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor;2. Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture;3. (i) SBIR and STTR. Be a concern which is more than 50 percent directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50 percent directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR(ii) SBIR-only. Be a concern which is more than 50 percent owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50 percent of the concern; OR(iii) SBIR and STTR. Be a joint venture in which each entity to the joint venture must meet the requirements set forth in paragraph 3 (i) or 3 (ii) of this section. A joint venture that includes one or more concerns that meet the requirements of paragraph (ii) of this section must comply with § 121.705(b) concerning registration and proposal requirements.4. Has, including its affiliates, not more than 500 employees. |
Additional Information
| Agency Name:: | National Institutes of Health |
| Description:: | The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize well-validated hit compounds through medicinal chemistry, or at the Development stage, to advance development candidates through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN participants receive intellectual property rights to drug candidates developed through the program. |
| Link to Additional Information:: | |
| Grantor Contact Information:: | If you have difficulty accessing the full announcement electronically, please contact: |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Synopsis 2 | Expired and Re-issued as PAR-17-201 | Mar 09, 2017 |
| Synopsis 1 |
Package Status
Below are CLOSED Opportunity Package(s) no longer available for this Funding Opportunity:
Package No: 1
| Assistance Listings: | |
| Competition ID: | FORMS-C |
| Competition Title: | FORMS-C |
| Opportunity Package ID: | PKG00201515 |
| Opening Date: | Sep 21, 2014 |
| Closing Date: | Jun 07, 2016 |
| Agency Contact Information:: | eRA Commons Help Desk |
| Who Can Apply:: | Organization Applicants |
| mendatory_forms |
SF424 (R & R) [V2.0] PHS 398 Research Plan [V2.0] SBIR/STTR_Information [V1.1] Research and Related Senior/Key Person Profile (Expanded) [V2.0] Research And Related Other Project Information [V1.3] Research & Related Budget [V1.3] Project/Performance Site Location(s) [V2.0] PHS 398 Cover Page Supplement [V2.0] |
| optional_forms |
R & R Subaward Budget Attachment(s) Form 5 YR 30 ATT [V1.3] Planned Enrollment Report [V1.0] PHS 398 Cumulative Inclusion Enrollment Report [V1.0] |
Package No: 2
| Assistance Listings: | |
| Competition ID: | FORMS-D |
| Competition Title: | Use for due dates on or after May 25, 2016 |
| Opportunity Package ID: | PKG00223975 |
| Opening Date: | Jul 11, 2016 |
| Closing Date: | Mar 10, 2017 |
| Agency Contact Information:: | eRA Service Desk Monday to Friday 7 am to 8 pm ET http://grants.nih.gov/support/ |
| Who Can Apply:: | Organization Applicants |
| mendatory_forms |
SF424 (R & R) [V2.0] PHS 398 Cover Page Supplement [V3.0] Research And Related Other Project Information [V1.3] Project/Performance Site Location(s) [V2.0] Research and Related Senior/Key Person Profile (Expanded) [V2.0] Research & Related Budget [V1.3] PHS 398 Research Plan [V3.0] SBIR/STTR_Information [V1.1] |
| optional_forms |
R & R Subaward Budget Attachment(s) Form 5 YR 30 ATT [V1.3] PHS Inclusion Enrollment Report [V1.0] PHS Assignment Request Form [V1.0] |